Larvol Delta - Centrexion-Therapeutics-Announces-Publication-of-Phase-2-Efficacy-Data-on-CNTX4975-for-Treatment-of-Moderate-to-Severe-Knee-Osteoarthritis-Pain-in-Arthritis-amp-Rheumatology

CNTX-4975 - Centrexion Corporation

http://www.globenewswire.com/news-release/2019/03/27/1773818/0/en/Centrexion-Therapeutics-Announces-Publication-of-Phase-2-Efficacy-Data-on-CNTX-4975-for-Treatment-of-Moderate-to-Severe-Knee-Osteoarthritis-Pain-in-Arthritis-Rheumatology.html

Mar 27, 2019

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next